Publication |
2013
Abstract
The introduction of tumor necrosis factor-α (TNF-α) inhibitors represented a significant progress in the management of rheumatoid arthritis (RA) and other chronic inflammatory diseases. Golimumab a novel anti-TNF-α monoclonal antibody, has demonstrated significant efficacy in randomized, double-blind, placebo-controlled phase III trials in the treatment of RA, psoriatic arthritis (PsA), and ankylosing spondylitis (AS) when administered subcutaneously once every four weeks.
This review summarizes the development of golimumab, its pharmacokinetic properties and clinical evidence achieved with golimumab in treatment of patients with rheumatoid arthritis.